- Home
- VKTX
as 08-15-2025 4:00pm EST
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.5B | IPO Year: | 2015 |
| Target Price: | $86.92 | AVG Volume (30 days): | 4.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.92 - $81.73 | Next Earning Date: | 07-23-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 338.60% |
Latest Viking Therapeutics Inc. News
VKTX Breaking Stock News: Dive into VKTX Ticker-Specific Updates for Smart Investing
Motley Fool
2 months ago
Why This Weight Loss Drug Company's Stock Surged Today
Clinical Trials Arena
2 months ago
Viking commences Phase III clinical programme of VK2735 for obesity
Zacks
2 months ago
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735
Motley Fool
2 months ago
3 Growth Stocks I'm Loading Up On
Investor's Business Daily
2 months ago
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity
MT Newswires
2 months ago
Viking Therapeutics Begins Phase 3 Trial of Dual Agonist VK2735 in Obesity
PR Newswire
2 months ago
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
Motley Fool
2 months ago
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Compare VKTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VKTX Viking Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.